These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Huttner A; Dayer JA; Yerly S; Combescure C; Auderset F; Desmeules J; Eickmann M; Finckh A; Goncalves AR; Hooper JW; Kaya G; Krähling V; Kwilas S; Lemaître B; Matthey A; Silvera P; Becker S; Fast PE; Moorthy V; Kieny MP; Kaiser L; Siegrist CA; Lancet Infect Dis; 2015 Oct; 15(10):1156-1166. PubMed ID: 26248510 [TBL] [Abstract][Full Text] [Related]
8. Rapid Protection from COVID-19 in Nonhuman Primates Vaccinated Intramuscularly but Not Intranasally with a Single Dose of a Vesicular Stomatitis Virus-Based Vaccine. Furuyama W; Shifflett K; Pinski AN; Griffin AJ; Feldmann F; Okumura A; Gourdine T; Jankeel A; Lovaglio J; Hanley PW; Thomas T; Clancy CS; Messaoudi I; O'Donnell KL; Marzi A mBio; 2022 Feb; 13(1):e0337921. PubMed ID: 35012339 [TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of GamEvac-Combi, a heterologous VSV- and Ad5-vectored Ebola vaccine: An open phase I/II trial in healthy adults in Russia. Dolzhikova IV; Zubkova OV; Tukhvatulin AI; Dzharullaeva AS; Tukhvatulina NM; Shcheblyakov DV; Shmarov MM; Tokarskaya EA; Simakova YV; Egorova DA; Scherbinin DN; Tutykhina IL; Lysenko AA; Kostarnoy AV; Gancheva PG; Ozharovskaya TA; Belugin BV; Kolobukhina LV; Pantyukhov VB; Syromyatnikova SI; Shatokhina IV; Sizikova TV; Rumyantseva IG; Andrus AF; Boyarskaya NV; Voytyuk AN; Babira VF; Volchikhina SV; Kutaev DA; Bel'skih AN; Zhdanov KV; Zakharenko SM; Borisevich SV; Logunov DY; Naroditsky BS; Gintsburg AL Hum Vaccin Immunother; 2017 Mar; 13(3):613-620. PubMed ID: 28152326 [TBL] [Abstract][Full Text] [Related]
10. Ebola vaccine trials: progress in vaccine safety and immunogenicity. Matz KM; Marzi A; Feldmann H Expert Rev Vaccines; 2019 Dec; 18(12):1229-1242. PubMed ID: 31779496 [No Abstract] [Full Text] [Related]
11. Attenuated Human Parainfluenza Virus Type 1 Expressing Ebola Virus Glycoprotein GP Administered Intranasally Is Immunogenic in African Green Monkeys. Lingemann M; Liu X; Surman S; Liang B; Herbert R; Hackenberg AD; Buchholz UJ; Collins PL; Munir S J Virol; 2017 May; 91(10):. PubMed ID: 28250127 [TBL] [Abstract][Full Text] [Related]
12. Designing Efficacious Vesicular Stomatitis Virus-Vectored Vaccines Against Ebola Virus. Wong G; Qiu X Methods Mol Biol; 2016; 1403():245-57. PubMed ID: 27076134 [TBL] [Abstract][Full Text] [Related]
14. Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens. Fathi A; Dahlke C; Addo MM Hum Vaccin Immunother; 2019; 15(10):2269-2285. PubMed ID: 31368826 [TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study. Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP; Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591 [TBL] [Abstract][Full Text] [Related]
16. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine. Wong G mBio; 2019 Jul; 10(4):. PubMed ID: 31311887 [TBL] [Abstract][Full Text] [Related]